Status: Recruiting
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
This is an Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of IMC-002 in Patients with Advanced Cancer Failed to Standard Therapy
Participants needed: 62
Trial details
Phase: Phase 1Age: 19+Biological sex: AllType: InterventionalSponsor: ImmuneOncia Therapeutics Inc.Updated: Apr 24, 2026Locations: 3
Eligibility criteria
Signed ICF [+23]
Treatment with nonpermitted drugs [+10]